Please login to the form below

Not currently logged in
Email:
Password:

Durbin appoints US business development principal

Todd Galles now takes up the role on a permanent basis

Durbin Todd GallesSpecialist medical supplier Durbin has appointed Todd Galles as its business development principal in the US in a permanent capacity.

Galles first joined the UK-headquartered firm in 2014, serving as its US representative in a part-time role, and will now be responsible for growing its clinical trial supply and managed access business there.

He brings over 30 years of sales, marketing and business development experience in the pharma and biotech industries, and has held a number of executive management roles during this time.

Prior to joining Durbin, Galles served as director of business development at C3 Research Associates, business development US liaison for Japanese contract research organisation CMIC, and business development director at US firm BDC.

He also brings experience from dermatology CRO bioskin, medical device and biotech CRO Boston Biomedical Associates, and clinical and data management firm ProPharma Group.

Robert Donnell, head of business development at Durbin, said: “Todd has supported business development outreach in the US part-time for Durbin for more than two years, so now we're delighted to have him on-board full-time.

“Todd brings a huge amount of experience and enthusiasm to the role, and I look forward to continuing to work with him to develop and grow our US business.”

26th September 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics